Chronic Limb-Threatening Ischemia

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day wound complication rates (9.7% vs 3.7%; adjusted OR 2.75, 95% CI 1.71-4.42) and higher blood transfusion or secondary pro

Effect: adverse; OR 2.75; CI: 95% CI 1.71-4.42

Bypass-first revascularization was associated with significantly higher 30-day wound complication rates (9.7% vs 3.7%; adjusted OR 2.75, 95% CI 1.71-4.42) and higher blood transfusion or secondary pro

Effect: adverse; OR 2.75; CI: 95% CI 1.71-4.42

Bypass-first revascularization was associated with significantly higher 30-day wound complication rates (9.7% vs 3.7%; adjusted OR 2.75, 95% CI 1.71-4.42) and higher blood transfusion or secondary pro

Effect: adverse; OR 2.75; CI: 95% CI 1.71-4.42

Bypass-first revascularization was associated with significantly higher 30-day wound complication rates (9.7% vs 3.7%; adjusted OR 2.75, 95% CI 1.71-4.42) and higher blood transfusion or secondary pro

Effect: adverse; OR 2.75; CI: 95% CI 1.71-4.42

Bypass-first revascularization was associated with significantly higher 30-day wound complication rates (9.7% vs 3.7%; adjusted OR 2.75, 95% CI 1.71-4.42) and higher blood transfusion or secondary pro

Effect: adverse; OR 2.75; CI: 95% CI 1.71-4.42

Bypass-first revascularization was associated with significantly higher 30-day wound complication rates (9.7% vs 3.7%; adjusted OR 2.75, 95% CI 1.71-4.42) and higher blood transfusion or secondary pro

Effect: adverse; OR 2.75; CI: 95% CI 1.71-4.42

Bypass-first revascularization was associated with significantly higher 30-day wound complication rates (9.7% vs 3.7%; adjusted OR 2.75, 95% CI 1.71-4.42) and higher blood transfusion or secondary pro

Effect: adverse; OR 2.75; CI: 95% CI 1.71-4.42

Bypass-first revascularization was associated with significantly higher 30-day wound complication rates (9.7% vs 3.7%; adjusted OR 2.75, 95% CI 1.71-4.42) and higher blood transfusion or secondary pro

Effect: adverse; OR 2.75; CI: 95% CI 1.71-4.42

Bypass-first revascularization was associated with significantly higher 30-day wound complication rates (9.7% vs 3.7%; adjusted OR 2.75, 95% CI 1.71-4.42) and higher blood transfusion or secondary pro

Effect: adverse; OR 2.75; CI: 95% CI 1.71-4.42

Bypass-first revascularization was associated with significantly higher 30-day wound complication rates (9.7% vs 3.7%; adjusted OR 2.75, 95% CI 1.71-4.42) and higher blood transfusion or secondary pro

Effect: adverse; OR 2.75; CI: 95% CI 1.71-4.42

Bypass-first revascularization was associated with significantly higher 30-day wound complication rates (9.7% vs 3.7%; adjusted OR 2.75, 95% CI 1.71-4.42) and higher blood transfusion or secondary pro

Effect: adverse; OR 2.75; CI: 95% CI 1.71-4.42

Bypass-first revascularization was associated with significantly higher 30-day wound complication rates (9.7% vs 3.7%; adjusted OR 2.75, 95% CI 1.71-4.42) and higher blood transfusion or secondary pro

Effect: adverse; OR 2.75; CI: 95% CI 1.71-4.42

Bypass-first revascularization was associated with significantly higher 30-day wound complication rates (9.7% vs 3.7%; adjusted OR 2.75, 95% CI 1.71-4.42) and higher blood transfusion or secondary pro

Effect: adverse; OR 2.75; CI: 95% CI 1.71-4.42

Bypass-first revascularization was associated with significantly higher 30-day wound complication rates (9.7% vs 3.7%; adjusted OR 2.75, 95% CI 1.71-4.42) and higher blood transfusion or secondary pro

Effect: adverse; OR 2.75; CI: 95% CI 1.71-4.42

Bypass-first revascularization was associated with significantly higher 30-day wound complication rates (9.7% vs 3.7%; adjusted OR 2.75, 95% CI 1.71-4.42) and higher blood transfusion or secondary pro

Effect: adverse; OR 2.75; CI: 95% CI 1.71-4.42

Bypass-first revascularization was associated with significantly higher 30-day wound complication rates (9.7% vs 3.7%; adjusted OR 2.75, 95% CI 1.71-4.42) and higher blood transfusion or secondary pro

Effect: adverse; OR 2.75; CI: 95% CI 1.71-4.42

Bypass-first revascularization was associated with significantly higher 30-day wound complication rates (9.7% vs 3.7%; adjusted OR 2.75, 95% CI 1.71-4.42) and higher blood transfusion or secondary pro

Effect: adverse; OR 2.75; CI: 95% CI 1.71-4.42

Bypass-first revascularization was associated with significantly higher 30-day wound complication rates (9.7% vs 3.7%; adjusted OR 2.75, 95% CI 1.71-4.42) and higher blood transfusion or secondary pro

Effect: adverse; OR 2.75; CI: 95% CI 1.71-4.42

Bypass-first revascularization was associated with significantly higher 30-day wound complication rates (9.7% vs 3.7%; adjusted OR 2.75, 95% CI 1.71-4.42) and higher blood transfusion or secondary pro

Effect: adverse; OR 2.75; CI: 95% CI 1.71-4.42

Bypass-first revascularization was associated with significantly higher 30-day wound complication rates (9.7% vs 3.7%; adjusted OR 2.75, 95% CI 1.71-4.42) and higher blood transfusion or secondary pro

Effect: adverse; OR 2.75; CI: 95% CI 1.71-4.42

Bypass-first revascularization was associated with significantly higher 30-day wound complication rates (9.7% vs 3.7%; adjusted OR 2.75, 95% CI 1.71-4.42) and higher blood transfusion or secondary pro

Effect: adverse; OR 2.75; CI: 95% CI 1.71-4.42

Bypass-first revascularization was associated with significantly higher 30-day wound complication rates (9.7% vs 3.7%; adjusted OR 2.75, 95% CI 1.71-4.42) and higher blood transfusion or secondary pro

Effect: adverse; OR 2.75; CI: 95% CI 1.71-4.42

Bypass-first revascularization was associated with significantly higher 30-day wound complication rates (9.7% vs 3.7%; adjusted OR 2.75, 95% CI 1.71-4.42) and higher blood transfusion or secondary pro

Effect: adverse; OR 2.75; CI: 95% CI 1.71-4.42